SLC6A8 and non-small cell lung carcinoma: Since SLC6A8 is highly expressed in NSCLC and associated with a poor prognosis, the AL513318.2/hsa-miR-26a-5p/SLC6A8 regulatory network could be used as a biomarker for poor prognosis and a new target for the treatment of NSCLC (Figure 4E).